Workers here earn their keep. Photo by Tom Werner/Getty Images

Houston is proving its worth as a robust employment center.

A new report from Dallas-based ThinkWhy, a producer of talent intelligence software, ranks the Bayou City No. 8 overall in the top-performing labor markets in the country.

The Greater Houston area scored highly in net migration, job gain, and college degree holders, per ThinkWhy's LaborIQ Market Index.

Meanwhile, Houston is expected to fully recover jobs lost to the pandemic by 2023, the report adds.

Elsewhere in Texas, Dallas-Fort Worth clocks in as the No. 1 metro labor market, Austin comes in at No. 3, and San Antonio at No. 24. The most recent index is based on 10 key economic indicators from September for 150 metro areas.

"All four of Texas' major metros — which rank among the largest in the country — are expected to remain top-performing metros for an extended period. Due to the sheer size of these labor markets, their recovery will significantly impact the national economy," ThinkWhy says.

In August, Austin became one of the three largest metros — along with Salt Lake City and Phoenix — to recover all jobs lost to the pandemic, according to ThinkWhy. DFW and San Antonio are set to join those ranks 2022, with Houston expected to fully recover lost jobs in 2023.

"Retention of talent will be a major risk for businesses the remainder of this year," Jay Denton, chief labor market analyst at ThinkWhy, says in a news release. "With a record number of job openings, businesses are trying different methods to retain and attract employees, and compensation has been a critical part of that equation."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”